

## Oasmia transfers Nordic commercialization rights for Apealea® to Inceptua

Stockholm, Sweden, 28 June 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces that it has entered into an agreement to transfer the rights for the commercialization of Apealea® (paclitaxel micellar) in the Nordics and Baltics to Inceptua Group ('Inceptua'), effective immediately. Inceptua already has exclusive rights for the commercialization of Apealea in the rest of Europe, following an agreement signed with Oasmia's global strategic partner for Apealea, Elevar Therapeutics, Inc. in 2020.

Apealea is approved by the European regulatory authorities for use in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Under the terms, Inceptua now possesses the rights to commercialize Apealea throughout the whole of Europe. Oasmia will be eligible for double-digit royalties on sales.

**François Martelet, M.D., CEO of Oasmia, commented:** "This agreement allows Oasmia to continue streamlining operations as we focus on expanding our oncology development pipeline. Elevar has selected Inceptua as they are an ideal partner for Apealea in the Nordics and Baltics and in the best position to make a success of commercializing Apealea in Europe, with strong capabilities and suitable infrastructure."

### For More Information:

#### Oasmia Pharmaceutical AB

Francois Martelet, Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: [IR@oasmia.com](mailto:IR@oasmia.com)

#### Consilium Strategic Communications (For Oasmia)

Jonathan Birt, Chris Welsh, Ashley Tapp

Phone: +44 (0)20 3709 5700

E-mail: [oasmia@consilium-comms.com](mailto:oasmia@consilium-comms.com)

#### About Oasmia Pharmaceutical AB

Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Oasmia's most advanced program is Apealea® (paclitaxel micellar), which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia's proprietary drug delivery platform XR-17™ is designed to improve drug solubility, efficacy and safety. Oasmia's shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit [www.oasmia.com](http://www.oasmia.com).

### **About Inceptua Group**

Inceptua is a specialty pharmaceutical company and a premium global service partner. Inceptua Pharma commercializes and markets orphan and specialty care products and have the expertise and capabilities to supply unlicensed medicines globally. Inceptua Services supports pharma and biotech companies with global clinical trial comparator sourcing, packaging, and labelling solutions, pre-approval and medicines access programs and consulting

Inceptua partners with life science companies of all sizes, drawing on over 20 years of industry experience, and has global operations with local offices across Europe, North America and Asia. Additional information is available at [www.inceptua.com](http://www.inceptua.com).

### **Attachments**

---

[Oasmia transfers Nordic commercialization rights for Apealea® to Inceptua](#)